<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132806">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887678</url>
  </required_header>
  <id_info>
    <org_study_id>C1301</org_study_id>
    <nct_id>NCT01887678</nct_id>
  </id_info>
  <brief_title>Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee</brief_title>
  <acronym>MOZArT</acronym>
  <official_title>A Multi-center Double-blind, Randomized, Controlled Trial to Evaluate the Effectiveness and Safety of Co-administered Traumeel® and Zeel® Intra-articular Injections Versus Placebo Intra-articular Injections in Patients With Moderate-to-Severe Pain Associated With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biologische Heilmittel Heel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biologische Heilmittel Heel GmbH</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness and safety of a combined Traumeel®
      /Zeel® injection against placebo in patients with moderate-to-severe pain associated with
      osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in knee pain as measured by the WOMAC Osteoarthritis (OA) Index Pain Subscale (Section A, Items #1-5) measured by 100 mm VAS</measure>
    <time_frame>from Baseline (Day 1, predose) to End of Study Visit (up to Day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain subscore (WOMAC Section A, Items #1-5) measured by 100 mm VAS</measure>
    <time_frame>from Baseline to post-Baseline visits except End of Study Visit (up to day 105)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical function subscore (WOMAC Section C, Items #8-24) recorded on 100 mm VAS</measure>
    <time_frame>from Baseline (Day 1, predose) to End of Study Visit (up to Day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total WOMAC score (all subscales) recorded on 100 mm VAS</measure>
    <time_frame>from Baseline (Day 1, predose) to End of Study Visit (up to Day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient global assessment (PGA) and physician global assessment (PhGA)</measure>
    <time_frame>from Baseline (Day 1, predose) to End of Study Visit (up to Day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain immediately following the 50-foot walk (100 mm VAS)</measure>
    <time_frame>Baseline (Day 1, predose) to post-Baseline visits (up to day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to walking (50-foot walk test)</measure>
    <time_frame>Baseline (Day 1, predose) to post-Baseline visits (up to day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to 50% pain relief (study population measure statistically derived)</measure>
    <time_frame>Statistically derived</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to 100% pain relief (study population measure statistically derived)</measure>
    <time_frame>Statistically derived</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to and use of rescue medication (acetaminophen up to 3000 mg per day for breakthrough pain) (study population measure statistically derived)</measure>
    <time_frame>Statistically derived</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stiffness subscore (WOMAC Section B, Items #6-7) measured by 100 mm VAS</measure>
    <time_frame>from Baseline (Day 1, predose) to End of Study Visit (up to Day 119)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Each Adverse Event (AE)</measure>
    <time_frame>Starting at Visit 2/ Start of Lead-In period (Day 7 up to day 119)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>during the treatment period and follow up period (Days 11 to 119)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Any TEAEs within each body system</measure>
    <time_frame>during the treatment period and follow up phase (Days 11 to 119)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients who discontinued due to an AE</measure>
    <time_frame>All visits (Days 1 up to 119)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Moderate-to-severe Pain Associated With Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Co-administered Traumeel® and Zeel®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo injectable solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traumeel® / Zeel® Injectable Solution</intervention_name>
    <description>Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.</description>
    <arm_group_label>Co-administered Traumeel® and Zeel®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo injectable solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Inclusion Criteria (Visit 1):

          1. OA of the knee by American College of Rheumatology criteria

          2. Men or women between 45-80 years of age.

          3. Have documented diagnosis of primary OA of the target knee based on clinical and
             radiographic criteria (Kellgren-Lawrence Numerical Grading System of Grade 2-3) in
             the tibial-femoral compartment of the target knee confirmed by standard post-anterior
             weightbearing X-ray of the knee in full extension taken &lt;/= 6 months prior to Visit
             1.

          4. Currently taking an Nonsteroidal anti-inflammatory drug (NSAID), or acetaminophen on
             a regular basis (4-7 days/ week) over last 2 weeks prior to Visit 1 and has
             experienced amelioration of pain on these medications.

          5. Must have a 50-foot walk test pain score of less than 40 mm on a 100 mm VAS in the
             target knee at screening

          6. Pain in the non-target (contralateral) knee must not be greater than 30 mm on a 100
             mm VAS on 50-foot walk test, and the target knee must be more symptomatic.

          7. Willingness to stop all OA treatments.

          8. Fully informed of the risks of entering the study and willing to provide written
             consent to enter the study.

          9. Able to understand and be willing to comply with all study requirements, particularly
             the weekly injection regimen for administration of study drug.

        Baseline Inclusion Criteria for Randomization (Visit 3):

        1. Primary complaint is pain immediately following an unassisted 50-foot walk. They must
        show:

          1. moderate to severe pain score in the target knee as demonstrated by 40 - 90 mm
             recorded on a 100 mm VAS, and

          2. 20 mm increase in pain from their screening visit pain score (a &quot;flare&quot;)

          3. pain in the non-target (contralateral) knee must &lt;/= 30 mm on a 100 mm VAS

        Exclusion Criteria:

          1. Known hypersensitivity or allergy to any of the components of Traumeel or Zeel

          2. Known hypersensitivity or allergy to acetaminophen.

          3. Has body mass index (BMI) &gt;38 kg/m2.

          4. Avoidance of, or aversion to, nonprescription medications.

          5. Clinical symptoms of meniscal instability or significant valgus/ varus that requires
             corrective osteotomy

          6. Has had any major injury or surgery to the target knee in the prior 12 months.

          7. Has one or a combination of the following co-morbidities:

               1. other inflammatory arthropathies, gout or pseudogout within previous 6 months

               2. avascular necrosis

               3. severe bone or joint deformity in target knee

               4. osteonecrosis of either knee

               5. fibromyalgia

               6. pes anserine bursitis

               7. lumbar radiculopathy with referred pain to either knee

               8. neurogenic or vascular claudication

               9. significant anterior knee pain due to diagnosed isolated patella-femoral
                  syndrome in the target knee

              10. target knee joint infection or skin disorder/infection to the area surrounding
                  the knee within previous 6 months

              11. current treatment or treatment of cancer within the previous 2 years (excluding
                  basal cell or squamous cell carcinoma of the skin)

          8. Has participated in any experimental drug or device study within the prior one (1)
             month and/or IA injections six (6) months.

          9. Has referred pain from other joints

         10. Has significantly debilitating concurrent infection(s)

         11. Significant ligamentous instability

         12. Any prior viscosupplementation therapy (in target knee) within 6 months prior to
             Screening

         13. Systemic or IA injection of corticosteroids in any joint within 3 months of enrolment

         14. Therapy with oral hyaluronic acid products, and/or oral pharmaceutical products
             containing glucosamine and/or chondroitin sulphate and/or diacerein

         15. Therapy with opioids within the last 90 days including intra-dermal delivery systems
             (patches)

         16. Therapy with autologous stem cells

         17. Therapy with coumarins such as warfarin, Coumadin; heparin and derivative substances
             including low molecular weight heparin, synthetic pentasaccharide inhibitors of
             factor Xa such as fondaparinux and idraparinux; direct factor Xa inhibitors such as
             rivaroxaban and apixaban; direct thrombin inhibitors such as hirudin, lepirudin,
             bivalirudin, argatroban and dabigatran.

         18. Concomitant inflammatory or other rheumatologic, neurological or cardiovascular
             diseases which could affect the evaluation of knee pain

         19. Ongoing litigation for workers compensation for musculoskeletal injuries or disorders

         20. Use of alcohol of more than 4 drinks per day

         21. Clinically important axial deviation (varus, valgus) greater than 15 degrees

         22. Concomitant severe OA of the hip or other joints, which might interfere with the
             assessments required by the study

         23. Painful knee conditions other than OA (e.g., Paget's disease)

         24. Hemiparesis of lower limbs

         25. Significant planned surgery to lower limbs, which might interfere with the patient's
             ability to comply with study requirements

         26. Presence of serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular,
             neurological disease that might interfere with the outcome of the study or the
             patient's ability to comply with study requirements

         27. Presence of infections and/or skin diseases in the area of the injection site such as
             psoriasis

         28. Females who are pregnant or breast-feeding or not using recognized effective
             contraceptive measures. Females of childbearing potential (including those less than
             one year post-menopausal) must agree to maintain reliable birth control throughout
             the study, i.e., an established use of oral, injected or implanted hormonal
             contraception, female sterilization by hysterectomy, bilateral oophorectomy, or
             bilateral tubal exeresis, intrauterine device (IUD) or coil or barrier method (e.g.,
             diaphragm, cervical/ vault cap) plus spermicidal cream/ gel

         29. Clinically significant abnormal laboratory values (as judged by the investigator) at
             the Screening visit

         30. Patients who are likely to be non-compliant or uncooperative during the study, as
             judged by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nebojsa Skrepnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tucson Orthopaedic Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Royal Anspach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Advantage - Arizona II</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Barthel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hans Richard Barthel, M.D., Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shariar Cohen-Gadol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westlake Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Bolshoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research Inc. - Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Murray, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Hole, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riverside Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustin Latorre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AppleMed Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Radnovich, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Injury Care Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moges Sisay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Scientific Innovations</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larkin T Wadsworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sundance Clinical Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurian Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Hope Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rakesh Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Salisbury</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Raad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Charlotte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin VanCleeff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Cary Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Rubino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Raleigh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard R Adelglass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Across America - NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Re, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Whitmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Inquest Center Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research Inc. - Akron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rakesh Davit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sterling Research Group, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenn Smith, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hillcrest Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawn Saylor, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blair Orthopedic Associates, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex Slandzicki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sadia Dar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rickey Manning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Knoxville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Wakefield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Knoxville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael R Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research Inc. - Salt Lake City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Sligh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David. Cardona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universal BioPharma Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Advantage - Arizona II</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universal BioPharma Research Inc.</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>N. Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hans Richard Barthel, M.D., Inc.</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Research</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc. - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AppleMed Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Injury Care Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Scientific Innovations</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research, LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America - NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Cary Medical Research</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hope Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc. - Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Inquest Center Ltd.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Orthopedic Associates, Inc.</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc. - Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
